Media stories about AcelRx Pharmaceuticals (NASDAQ:ACRX) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 46.2279396476543 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

AcelRx Pharmaceuticals (ACRX) opened at $1.90 on Tuesday. AcelRx Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $5.75. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78.

A number of equities research analysts have commented on ACRX shares. Royal Bank Of Canada set a $6.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of AcelRx Pharmaceuticals in a research note on Tuesday, October 3rd. Stifel Nicolaus upgraded AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Roth Capital set a $13.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 2nd. Finally, ValuEngine cut AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. AcelRx Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $6.83.

COPYRIGHT VIOLATION NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at

In other news, insider Lawrence G. Hamel sold 10,161 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $5.29, for a total value of $53,751.69. Following the completion of the transaction, the insider now directly owns 16,379 shares in the company, valued at $86,644.91. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Vincent J. Angotti bought 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were bought at an average cost of $3.00 per share, for a total transaction of $45,000.00. Following the completion of the acquisition, the chief executive officer now owns 15,000 shares of the company’s stock, valued at $45,000. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 42,000 shares of company stock valued at $121,980. Company insiders own 28.10% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Insider Buying and Selling by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.